Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 06 June, 2007

XTL Biopharm Ltd

XTL Provides Update on Ph I Clinical Trial of X...

           XTL Provides Update on Phase I Clinical Trial of XTL-2125           

Valley Cottage, New York, June 6, 2007 -- XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) announced today that it has completed the analysis
of results from a Phase I clinical trial with XTL-2125 in patients with chronic
Hepatitis C. This Phase I trial was a placebo controlled, randomized, dose
escalating study, which evaluated the safety, tolerability and antiviral
activity of single and multiple doses of XTL-2125. The study enrolled 56
patients into seven cohorts comprised of eight patients each (of which two are
placebo patients). Each patient received a single dose, followed by a 14-day
multi-dosing regimen commencing one week after the single dose administration.
The highest daily multi-dose regimen that was evaluated in the trial was 1800mg
per day (600mg three times per day).

The analysis of the data indicates that XTL-2125 was generally well tolerated.
However, HCV-RNA viral load reductions in patients treated with XTL-2125 were
not significantly different from those observed in the placebo group. Based on
these results, XTL has decided to suspend further development of XTL-2125.

XTL's CEO, Ron Bentsur, commented: "The completion of this Phase I trial
concludes our research on the XTL legacy compounds that we inherited. Through
an aggressive business development effort, XTL's new management team has
successfully reinvented the company's product portfolio - with Bicifadine as a
lead product in late stage clinical development, and the XTL-DOS program, which
is emerging as a very promising program in Hepatitis C. We look forward to an
exciting rest of 2007, with the initiation of a late-stage clinical trial with
Bicifadine in chronic neuropathic pain, and the initiation of IND-enabling
studies with a novel hepatitis C inhibitor from the XTL-DOS program. We will
also continue to opportunistically seek to broaden our portfolio through the
in-licensing and acquisitions of additional clinical stage products."

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
developing several novel pre-clinical hepatitis C small molecule inhibitors.
 XTL also has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:

Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225

Cautionary Statement
Some of the statements included in this press release, particularly those
anticipating future performance, clinical and business prospects for our
clinical compound for neuropathic pain, Bicifadine, and for our pre-clinical
compounds for hepatitis C from our XTL-DOS program, growth and operating
strategies and similar matters, may be forward-looking statements that involve
a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995. Among the factors that could
cause our actual results to differ materially are the following: our ability to
start a clinical trial with Bicifadine in 2007; our ability to successfully
complete cost-effective clinical trials for the drug candidates in our pipeline
which would affect our ability to continue to fund our operations with our
available cash reserves, our ability to meet anticipated development timelines
for the drug candidates in our pipeline due to recruitment, clinical trial
results, manufacturing capabilities or other factors; and other risk factors
identified from time to time in our reports filed with the Securities and
Exchange Commission and the London Stock Exchange, including our annual report
on Form 20-F filed with the Securities and Exchange Commission on March 23,
2007. Any forward-looking statements set forth in this press release speak only
as of the date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at http:// The information in our website is not incorporated by reference
into this press release and is included as an inactive textual reference only.


a d v e r t i s e m e n t